IMAB362 plus zoledronic acid (ZA) and interleukin-2 (IL-2) in patients (pts) with advanced gastroesophageal cancer (GEC): Clinical activity and safety data from the PILOT phase I trial

Autor:	Volker Brass, Peter C. Thuss-Patience, Ö. Türeci, Marianne Just, Salah-Eddin Al-Batran, Florian Lordick, Michael Bitzer, Wael Hozaeel, Jens Freiberg-Richter, Ugur Sahin, Zanete Zvirbule, Christian Mueller, Anna Krilova, Elmar Daalman
Rok vydání:	2015
Předmět:	Interleukin 2 Cancer Research medicine.medical_specialty Tight junction medicine.drug_class business.industry Monoclonal antibody Surgery Gastroesophageal cancer Zoledronic acid Oncology medicine Cancer research In patient Claudin business IMAB362 medicine.drug
Zdroj:	Journal of Clinical Oncology. 33:e15079-e15079
ISSN:	1527-7755 0732-183X
Popis:	e15079 Background: IMAB362 is the first-in-class monoclonal antibody against the tight junction molecule claudin 18.2 (CLDN18.2) executing its antitumor activity via 4 highly potent modes of action...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ffcbce7c687e98fb0f826eb94df10d99 https://doi.org/10.1200/jco.2015.33.15_suppl.e15079 Zobrazit plný text záznamu